Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 10/20 | 0.48 |
| ▸ | KDR | P35968 | 10/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67208 | 0.86 | PDGFRB (0.46) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL24354634 | 0.84 | LPL (0.46) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL392011 | 0.83 | GSK3A (0.39) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL17420905 | 0.83 | GSK3A (0.39) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL2067382 | 0.82 | PDGFRB (0.41) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL2067426 | 0.80 | PDGFRB (0.40) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL13693355 | 0.80 | PDGFRB (0.48) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL16279689 | 0.79 | PDGFRB (0.47) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL2271569 | 0.78 | PDGFRB (0.46) | PDGFRBKDRGSK3AGSK3BAAK1 | |
| SCHEMBL2066738 | 0.76 | PDGFRB (0.46) | PDGFRBKDRGSK3AGSK3BAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | PDGFRB 3232/4885KDR 1846/4885GSK3A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.